CTOs on the Move

IPS Research Company

www.ipsresearch.com

 
IPS Research Company is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Oklahoma City, OK. To find more information about IPS Research Company, please visit www.ipsresearch.com
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million
  • www.ipsresearch.com
  • 1111 N Lee Ave Ste 400
    Oklahoma City, OK USA 73103-2620
  • Phone: 405.235.8188

Executives

Name Title Contact Details

Similar Companies

Park View Care Ctr

Park View Care Ctr is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MedSpeed

Healthcare is changing. Healthcare organizations are growing. Care continues to expand outside of the hospital walls. This provides more capacity to utilize scale to create healthcare companies that are better functioning, smarter organizations. Intra-company logistics - the enterprise-wide movement of physical materials, such as blood and specimens, pharmaceuticals and supplies - is the foundation of the healthcare supply chain. Healthcare organizations, especially those providing service to patients` homes, need transportation to function. With 130+ locations in 29 states, MedSpeed is the market-leading organization that is changing the way the healthcare industry views transportation by leveraging it to help organizations integrate and operate more effectively.

Klearview Manor Nursing Home

Klearview Manor Nursing Home is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Klearview Manor Nursing Home is based in Fairfield, ME. You can find more information on Klearview Manor Nursing Home at www.northcountryassociates.com

Marimed Foundation

Marimed Foundation is a Kaneohe, HI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kolltan

Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.